SPONSOR
Innovent Biologics (Suzhou) Co. Ltd.
Total Trials
7
Recruiting
7
Phases
Phase 2, Phase 3, Phase 1, Phase 2
Conditions studied: Resectable Stage IB-III Non-Squamous Non-Small Cell Lung CancerSleep ApneaObstructiveObesityThyroid Eye DiseaseAtopic DermatitisSolid TumorMelanomaNon-small Cell Lung CancerColorectal Cancer
NCT07122687 Phase 2
Recruiting
IBI363 Combined With Chemotherapy or Pembrolizumab Combined With Chemotherapy as Neoadjuvant Therapy in Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
Resectable Stage IB-III Non-Squamous Non-Small Cell Lung Cancer
NCT06931028 Phase 3
Recruiting
A Study of IBI362 in Chinese Subjects With Obstructive Sleep Apnea and BMI≥28 kg/m2
Sleep Apnea
NCT07113262 Phase 3
Recruiting
A Clinical Study to Evaluate the Efficacy and Safety of IBI311 in Subjects With Inactive Thyroid Eye Disease
Thyroid Eye Disease
NCT07399067 Phase 2
Recruiting
A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis
Atopic Dermatitis
NCT05923008 Phase 1, Phase 2
Recruiting
A Clinical Study of IBI130 for Subjects With Unresectable, Locally Advanced or Metastatic Solid Tumors
Solid Tumor
NCT06281678 Phase 2
Recruiting
A Study of IBI363 in Subjects with Advanced Solid Malignancies
Melanoma
NCT06937749 Phase 2
Recruiting
A Study of IBI362 in Participants With Metabolic Dysfunction-Associated Steatohepatitis (MASH)
Metabolic Dysfunction-associated Steatohepatitis (MASH)